Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
EDQM
0
USP
0
JP
0
Others
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
API
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
1. Nu-9
2. Akv9
3. Ssz5c8u4kq
4. Akv-9
5. Chembl2089305
6. Schembl12676303
7. Fvevqubfqxfsny-qmmmgpobsa-n
8. 1,3-cyclohexanedione, 5-[(1s)-1-[3,5-bis(trifluoromethyl)phenoxy]ethyl]-
9. 5-[(1s)-1-[3,5-bis(trifluoromethyl)phenoxy]ethyl]-1,3-cyclohexanedione
10. 1307262-15-2
| Molecular Weight | 368.27 g/mol |
|---|---|
| Molecular Formula | C16H14F6O3 |
| XLogP3 | 3.7 |
| Hydrogen Bond Donor Count | 0 |
| Hydrogen Bond Acceptor Count | 9 |
| Rotatable Bond Count | 3 |
| Exact Mass | g/mol |
| Monoisotopic Mass | g/mol |
| Topological Polar Surface Area | 43.4 |
| Heavy Atom Count | 25 |
| Formal Charge | 0 |
| Complexity | 475 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 1 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Drugs in Development
Details:
The funding will support Akava’s lead compound, NU-9 (AKV9). It is being evaluated for the treatment of Alzheimer’s disease and frontotemporal dementia.
Lead Product(s): AKV9
Therapeutic Area: Neurology Brand Name: NU-9
Study Phase: IND EnablingProduct Type: Other Small Molecule
Sponsor: National Institute on Aging
Deal Size: $7.3 million Upfront Cash: Undisclosed
Deal Type: Funding December 17, 2024
Lead Product(s) : AKV9
Therapeutic Area : Neurology
Highest Development Status : IND Enabling
Partner/Sponsor/Collaborator : National Institute on Aging
Deal Size : $7.3 million
Deal Type : Funding
Akava Therapeutics Celebrates $7.3M Grant to Study AKV9 in Neurodegeneration
Details : The funding will support Akava’s lead compound, NU-9 (AKV9). It is being evaluated for the treatment of Alzheimer’s disease and frontotemporal dementia.
Product Name : NU-9
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
December 17, 2024
Details:
AKV9 (formerly NU-9) is a Protein aggregation inhibitor, which is being investigated in amyotrophic lateral sclerosis and improve the health of diseased upper motor neurons.
Lead Product(s): AKV9
Therapeutic Area: Neurology Brand Name: AKV9
Study Phase: IND EnablingProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 22, 2023
Lead Product(s) : AKV9
Therapeutic Area : Neurology
Highest Development Status : IND Enabling
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : AKV9 (formerly NU-9) is a Protein aggregation inhibitor, which is being investigated in amyotrophic lateral sclerosis and improve the health of diseased upper motor neurons.
Product Name : AKV9
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 22, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]ABOUT THIS PAGE
94
PharmaCompass offers a list of AKV9 API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right AKV9 manufacturer or AKV9 supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred AKV9 manufacturer or AKV9 supplier.
PharmaCompass also assists you with knowing the AKV9 API Price utilized in the formulation of products. AKV9 API Price is not always fixed or binding as the AKV9 Price is obtained through a variety of data sources. The AKV9 Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A 1307262-15-2 manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of 1307262-15-2, including repackagers and relabelers. The FDA regulates 1307262-15-2 manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. 1307262-15-2 API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A 1307262-15-2 supplier is an individual or a company that provides 1307262-15-2 active pharmaceutical ingredient (API) or 1307262-15-2 finished formulations upon request. The 1307262-15-2 suppliers may include 1307262-15-2 API manufacturers, exporters, distributors and traders.
1307262-15-2 Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of 1307262-15-2 GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right 1307262-15-2 GMP manufacturer or 1307262-15-2 GMP API supplier for your needs.
A 1307262-15-2 CoA (Certificate of Analysis) is a formal document that attests to 1307262-15-2's compliance with 1307262-15-2 specifications and serves as a tool for batch-level quality control.
1307262-15-2 CoA mostly includes findings from lab analyses of a specific batch. For each 1307262-15-2 CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
1307262-15-2 may be tested according to a variety of international standards, such as European Pharmacopoeia (1307262-15-2 EP), 1307262-15-2 JP (Japanese Pharmacopeia) and the US Pharmacopoeia (1307262-15-2 USP).
